Boceprevir

Boceprevir
	File:Boceprevir.svg
Identifiers
	IUPAC name (1R,2S,5S)-N-[(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)]- 3-{(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl}- 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
CAS Number	394730-60-0;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C27H45N5O5
Molar mass	519.69 g·mol−1

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Assistant Editor-In-Chief: Nina Axiotakis [2]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Boceprevir (INN) is a protease inhibitor being studied as a treatment for hepatitis C.^[1]^[2]

It is being developed by Schering-Plough.^[3] As of 2008, it is in phase II clinical trials.^[3]

References

↑ Degertekin B, Lok AS (2008). "Update on viral hepatitis: 2007". Curr. Opin. Gastroenterol. 24 (3): 306–11. doi:10.1097/MOG.0b013e3282f70285. PMID 18408458. Unknown parameter |month= ignored (help)
↑ Njoroge FG, Chen KX, Shih NY, Piwinski JJ (2008). "Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection". Acc. Chem. Res. 41 (1): 50–9. doi:10.1021/ar700109k. PMID 18193821. Unknown parameter |month= ignored (help)
↑ ^3.0 ^3.1 "Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL - Forbes.com" (Press release). Forbes.com. Retrieved 2008-05-19.

Template:WS

[pmid18408458-1] Degertekin B, Lok AS (2008). "Update on viral hepatitis: 2007". Curr. Opin. Gastroenterol. 24 (3): 306–11. doi:10.1097/MOG.0b013e3282f70285. PMID 18408458. Unknown parameter |month= ignored (help)

[pmid18193821-2] Njoroge FG, Chen KX, Shih NY, Piwinski JJ (2008). "Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection". Acc. Chem. Res. 41 (1): 50–9. doi:10.1021/ar700109k. PMID 18193821. Unknown parameter |month= ignored (help)

[PhaseII-3] 3.0 ^3.1 "Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL - Forbes.com" (Press release). Forbes.com. Retrieved 2008-05-19.

[1]

[2]

[3]

v t e Antivirals, other than for HIV (primarily J05, also S01AD and D06BB)
Anti-herpesvirus (DNA, I)	guanine analogues (Aciclovir, Famciclovir, Ganciclovir, Penciclovir, Valaciclovir, Valganciclovir) • nucleoside analogues (Idoxuridine, Trifluridine, Vidarabine) • Cidofovir • Docosanol • Fomivirsen • Foscarnet • Tromantadine
HPV/MC (DNA, I)	Imiquimod • Podophyllotoxin
Hepatitis B (DNA, VII)	Adefovir • Interferon alfa-2b • Pegylated interferon alfa-2a • Entecavir • Lamivudine • Telbivudine • Tenofovir^†
Hepatitis C (RNA, IV)	Pegylated interferon alpha • Ribavirin • Taribavirin^† • Boceprevir^†
Picornavirus (RNA, IV)	Pleconaril^†
Anti-influenza agents (RNA, V)	Arbidol adamantane derivatives/M2 inhibitors (Amantadine, Rimantadine) neuraminidase inhibitors (Oseltamivir, Zanamivir, Peramivir^†)
HIV (Reverse, VI)	See HIV pharm
Other antiviral agents	general (Inosine, Interferon)
^†Undergoing clinical trials, not FDA approved.

Identifiers
File:Boceprevir.svg
IUPAC name (1R,2S,5S)-N-[(2Ξ)-4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)]- 3-{(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl}- 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
CAS Number	394730-60-0
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₇H₄₅N₅O₅
Molar mass	519.69 g·mol⁻¹

Boceprevir

References

Navigation menu